• Consistent with a damaging role for increased LOX activity

  2024-05-08

  

  Consistent with a damaging role for increased 12/15-LOX activity in stroke, systemic administration of the 12/15-LOX inhibitor, LB1, 2 h after permanent focal cerebral ischemia significantly reduced infarct size 24 h after the ischemia, and the treatment group demonstrated improved behavioral and he

• Somatostatin analogs also bind to somatostatin receptors It

  2024-05-07

  

  Somatostatin analogs also bind to somatostatin receptors. It has been reported that octreotide has a high affinity for hSSTR2, moderate affinity for hSSTR3 and hSSTR5, and does not bind to hSSTR1 or hSSTR4 (Ben-Shlomo and Melmed 2008). Compared to octreotide, pasireotide displays 40-, 30-, and 5-fol

• br Conclusions A large body of

  2024-05-07

  

  Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we

• br Conclusion br Acknowledgments and disclosure

  2024-05-07

  

  Conclusion Acknowledgments and disclosure We thank Ms. Crystal Wylie for her help in the preparation of the manuscript. The development of the database upon which analyses of this study were dependent was supported by PO1 DC 00161 from the National Institute on Deafness and Other Communication

• A previous review article suggested different washout interv

  2024-05-07

  

  A previous review article suggested different washout intervals based on specific clinical contexts [4]. While no consensus was reached for the optimal interval between last dose of BV and surgery for CRLM, the authors of the review suggested waiting 6 to 8 weeks after BV before surgery, particularl

• What are the in situ effects of

  2024-05-07

  

  What are the in-situ effects of multi-site CaM associations with AT1R? Kai et al. showed that synthetic peptides corresponding to residues 125–137 (rat sequence) in SMD2, 217–227 in the N-terminal side of SMD3, and 304–316 in SMD4JM inhibit to various degrees AngII-induced GTPase activity of isolate

• br Conclusions br Declarations br Introduction The classical

  2024-05-07

  

  Conclusions Declarations Introduction The classical term of endocrine disruption includes any agent that interferes with the action of hormones within the human body; these agents are therefore named endocrine disruptors. Among these agents, that are mainly environmental chemicals (pollutan

• In addition to differential expression of AR

  2024-05-07

  

  In addition to differential expression of AR protein primarily in surgical specimens, genetic alterations involving the AR gene have been documented in human protease activated receptor cancer. Loss of heterozygosity at the AR locus was identified in all 3 informative cases of muscle-invasive bladde

• Sixth significant progress has been made during the last few

  2024-05-07

  

  Sixth, significant progress has been made during the last few years regarding the molecular mechanisms underlying the activation of AMPK and this should aid to develop more potent and specific compounds. Information from crystallographic structures combined with computer-based drug design hold promi

• br The lipoxygenase pathway in

  2024-05-07

  

  The 12/15-lipoxygenase pathway in vascular physiology and pathology The mammalian 12- and 15-LOXs have high substrate specificity oxidizing predominantly ω−6 (arachidonic and linoleic acids) but also the ω−3 (docosahexanoic) Moxidectin [86], [87], [88]. Different LOXs oxidize fatty acids both in

• br Disclosure br Acknowledgments br Introduction Anaplastic

  2024-05-07

  

  Disclosure Acknowledgments Introduction Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase, belongs to the insulin receptor kinase subfamily [1]. Oncogenic activation of ALK is associated with the Uridine and progression of multiple human cancer types [2,3], including anaplastic

• br Current therapies for metabolic diseases Inborn errors of

  2024-05-07

  

  Current therapies for metabolic diseases Inborn errors of metabolism caused by deficiency of particular enzymes due to loss of function mutations or deletions have been treated by decreasing the intake of the enzymatic substrate, supplementation with an essential cofactor or vitamin, increasing m

• These results from the present study are summarized in Table

  2024-05-07

  

  These results from the present study are summarized in Table 1. Eight drugs (doxorubicin, epirubicin, daunorubicin, idarubicin, irinotecan, imatinib, sunitinib and gefitinib) inhibited 5-HT-induced 5-HT3A and 5-HT3AB currents; three (irinotecan, topotecan and mitoxantrone) showed different responses

• To our knowledge BAY has not progressed to clinical developm

  2024-05-07

  

  To our knowledge, BAY 60-6583 has not progressed to clinical development and remains to be the only ADORA2B agonist that has been developed.33, 34 Further development of similar compounds would be beneficial in future fibrosis research. One of the limitations of our study is being limited to in vit

• Nowadays more than kinases have been identified of human

  2024-05-06

  

  Nowadays, more than 500 kinases have been identified of human genome [2]. Imatinib (Gleevec) was the first tyrosine kinase inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of chronic myeloid leukemia [3], and kinases have become an attractive target for the developme

14636 records 162/976 page Previous Next First page 上5页 161162163164165 下5页 Last page